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Rationale for review: Dengue is a frequent cause of febrile illness among travellers and has overtaken malaria as the leading cause of febrile illness 
for those traveling to South East Asia. The purpose is to review the risk of dengue and severe dengue in travellers with a particular focus on the 
pathogenesis and clinical management of severe dengue.  
Risk, pathogenesis and clinical management: The risk of travel-acquired dengue depends on destination, season and duration of travel and 
activities during travel. Seroconversion rates reported in travellers therefore vary between less than 1% to more than 20%. The most common life-
threatening clinical response to dengue infection is the dengue vascular permeability syndrome, epidemiologically linked to secondary infection, 
but can also occur in primary infection. Tertiary and quaternary infections are usually associated with mild or no disease.  Antibody-dependent 
enhancement, viral factors, age, host factors, and clinical experience of the managing physician modulate the risk of progressing to severe dengue. 
The reported relative risk of severe dengue in secondary versus tertiary infection ranges from 2 to 7. The absolute risk of severe dengue in highly 
endemic areas in children is about 0.1% per year for primary infections, and 0.4% for secondary infections. About 2-4% of secondary infections 
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lead to severe dengue. Severe dengue and death are both relatively rare in general travellers, but more frequently in those visiting friends and 
relatives (VFR). Clinical management of severe dengue depends on judicious use of fluid rehydration.  
Conclusions: Although dengue is a frequent cause of travel illness, severe dengue and deaths are rare. Nevertheless, dengue infections can 
interrupt travel, lead to evacuation and major out-of-pocket costs. Dengue is more frequent than many other travel-related vaccine preventable 
diseases such as hepatitis A, hepatitis B, rabies, Japanese encephalitis, and yellow fever, indicating a need for a dengue vaccine for travellers.  
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Introduction and objectives 
During the past 50 years, dengue viruses have emerged from an endemic focus in Southeast Asia to a global pandemic.1 Dengue infections 
are increasing at higher rates than any other communicable disease, with a 400% increase over 13 years (2000-2013) according to the Global 
Disease Burden study.2 Although still regarded a neglected tropical disease, investments in vaccine development and novel vector control 
measures have increased exponentially in the past decade.3 The four mosquito-borne dengue viruses are now endemic in urban and rural areas in 
more than 100 tropical and subtropical countries with annually 50- 100 million estimated cases.4  Many dengue endemic countries are well-known 
travel destinations with cultural or recreational features that attract visitors from around the world. Dengue is hence a frequent cause of febrile 
illness among travellers returning from Southeast Asia, Latin America or the Caribbean,5,6 and has overtaken malaria as the leading cause of 
febrile illness for those traveling to South East Asia.7 A tripling of hospitalization for dengue in US travellers was reported between 2000-2007.8 
There has been a corresponding increase in dengue reported in European travellers.9,10 Dengue can occur in tourist travellers, business travellers, 




Air travel between dengue-endemic countries and from dengue-endemic countries to non-endemic has increased exponentially, thus, 
travellers contribute to the global spread of dengue.20-25 About 36% of travellers who acquired dengue during travel to dengue endemic countries 
returned to Europe during the acute phase of the infection (up to 7 days after symptom onset), and 58% of travellers with an acute dengue infection 
were viraemic when seeking medical care, highlighting the risk of autochthonous infection if returning to areas where Aedes mosquitoes are 
present.26 Returning viraemic travellers may initiate local transmission although recent modeling estimated the potential for dengue establishment 
in Europe to be very low.27 Travellers also serve as sentinels to identify silent dengue transmission in particular in countries or continents that may 
underreport dengue such as Africa.28  
 The incubation time of dengue is 7-10 days.  Dengue is usually a self-limited acute febrile disease; however, hospitalization for dengue in 
travellers is fairly common6 and dengue illness can disrupt travel resulting in evacuations back home.29 In a study on travel-associated dengue, 
22% reported hospitalization and 32% receiving ambulatory care whilst travelling, these percentages were higher at 39% and 71%, respectively, 
after returning home.30 The out-of-pocket direct and indirect costs of dengue illness were US$421 and US$571 per episode, respectively, 
averaging to a total out-of-pocket cost of US$992 per episode, suggesting that international travellers incur important direct and indirect costs 
because of dengue-related illness.  
 When dengue illnesses are seen by health care workers unfamiliar with diagnostic features, misdiagnosis may delay treatment or result in 
mismanagement with increased risk of severe dengue with complications or death. The purpose is to review the risk of dengue in travellers and the 





(1) Dengue viruses and its vectors 
Human dengue infections are caused by any of the four dengue viruses, types 1, 2, 3 and 4. These are transmitted in a cycle from viraemic to 
susceptible hosts principally by Aedes aegypti mosquitoes, a species that has been immensely successful in surviving in human environments. The 
mosquito breeds in a huge variety of containers,large and small, throughout the tropical and subtropical world.  A secondary vector, Aedes 
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albopictus has recently spread from Asia to tropical, subtropical and temperate countries around the world.31 Sexual transmission of dengue virus 
as seen for Zika virus has not been shown for dengue, except for one probable instance.32,33 
 
(2) Pathogenesis of dengue and severe dengue 
Four immunologically distinct but ecologically and biologically identical dengue viruses often circulate in the same area. The 
pathophysiological responses to infections with the four dengue viruses in hosts differing in immune status make dengue a highly complex disease. 
Central to dengue pathogenesis is the ability of dengue viruses to target cells of mononuclear cell lineage.34 35  IgG antibodies residual from first  
infections form infectious immune complexes with a second infecting (different) dengue virus. These complexes attach to Fc receptors sending 
signals that partially cripple innate antiviral responses resulting in intrinsic antibody dependent enhanced infection (ADE). This may produce a 
hundred to thousand-fold increase in production of dengue virions in each infected cell. 36-39 Severe dengue disease accompanies second 
heterotypic dengue infections that occur no less than 2 – 3 years apart in at least 12 different sequences (e.g, DENV 1 followed by DENV 2, 
DENV 3 then 4, etc.). Unique in human medicine, dengue IgG placental antibodies from mothers with two or more lifetime dengue infections 
degrade from protective concentrations at birth to dengue disease enhancing concentrations several months later.40 In highly endemic SE Asian 
countries, severe dengue in infants comprise 5% of total hospitalizations of children.41  
The most common life-threatening clinical response to dengue infection is the dengue vascular permeability syndrome (DVPS). This is a 
febrile dengue infection that evolves to include a) Thrombocytopenia (b) Altered hemostasis: most commonly prolonged bleeding time and/or 
elevated aPTT (activated partial thromboplastin time) and/or elevated prothrombin time (c) Activated complement, by classical and alternative 
pathways (d) Elevated liver transaminase enzymes, and (e) Vascular permeability. 42 Significant fluid volume and small macromolecules (e.g., 
albumin) are lost from the circulation into interstitial spaces and commonly into serosal spaces. This fluid loss may occur rapidly and often starts 3 
or more days after onset of fever. During much of the early history of DVPS fluid loss from circulation was inferred from hematocrit values.43,44 
Today, ultrasound examination can detect fluid loss rapidly and sensitively.45,46 Peak vascular permeability accompanied by profound vascular 
instability usually accompanies defervescence.44,47 
Antibody-dependent enhancement (ADE) was postulated to be the pathophysiological mechanism triggering DVPS in the 1970`s, based 
on in-vitro studies.48 Recent discoveries with regards to dengue non-structural protein 1 (NS1) have added a disease inducing mechanism to a 
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kinetic phenomenon (ADE). Dengue NS1 that circulates in the blood throughout infection at high concentrations has direct toxic properties 
making dengue shock syndrome a viral analog of bacterial toxic shock syndrome. 49,50 DENV NS1 can produce endothelial hyperpermeability in 
vitro and vascular leak in vivo. In a mouse model circulating NS1 alone leads to vascular permeability, accompanied but not preceded by  
circulating levels of inflammatory cytokines.51 Meanwhile, a mystery prevails in understanding the pathophysiology. While in animal models, 
endothelial cells are rapidly damaged by DENV NS1, in humans, severe vascular permeability is a rare event. 52 Furthermore, vascular leakage is 
temporally linked to defervescence, a time when circulating levels of NS1 are low. Defervescence in viral diseases usually signals the termination 
of intracellular infection by cell-mediated immunity. Only a small fraction of secondary infections lead to severe disease. One reason may be a 
requirement for a low level of circulating dengue antibodies. Prospective cohort studies have shown that children who had severe secondary 
infections had baseline pre-infection antibodies within a certain titer range.53,54 
Besides ADE, viral factors play a role with some serotypes and genotypes expressing higher rates of overt dengue disease outcomes than 
others.55  Amino acid substitutions that change the subtype or clade within a genotype can influence transmission dynamics. The DENV-2 
epidemic in Cuba in 1997 was attributed to a single amino acid substitution in the NS1 protein compared to the DENV-2 that had been present on 
the island prior to the epidemic.56 Dengue virus serotype 2 is also more often associated with severe dengue than other serotypes.57Age-related 
differences in microvascular permeability are also significant factors making infants more susceptible to dengue shock.58 Genetic host factors are 
also important: a genome-wide association study identified susceptibility loci for dengue shock syndrome at two loci.59  Host factors also 
contribute to clinical outcome of DENV infections genes in the lipid and steroid metabolism pathways.59  Polymorphisms in the genes that encode 
proteins that function in pathways that link lipid metabolism with immune response may explain the reduced susceptibility of the black race to 
severe dengue.60 However, the broad background flavivirus exposure observed frequently in Africa may result in cross-protection contributing to 
less severe dengue disease in Africa. More research is needed with regards to the influence of race.  
Preexisting high antibody titers to dengue virus were associated with reduced risk of ZIKV infection and symptoms.61 The 2015-2016 Zika 
epidemic in the American tropics resulted in an approximately 80% reduction in reported dengue cases in 2017–18.62  More research is needed to 
address the possible immunological mechanisms of cross-protection between ZIKV and DENV and whether DENV immunity also modulates 
other ZIKV infection outcomes such as neurological or congenital syndromes63, but preliminary data suggests that a previous DENV infection 




Risk of dengue in travellers  
 
About 128 countries are potential travel destinations where dengue virus is circulating.65 GeoSentinel is a global network of travel medicine 
providers who attend to returning travellers66: GeoSentinel has documented an increase of dengue in returning travellers over the past decades.67,68  
In Southeast Asia, annual proportionate morbidity increased from 50 dengue cases per 1,000 ill returned travellers in non-epidemic years to an 
average of 159 cases per 1,000 travellers during epidemic years.7 The intensity of dengue transmission is influenced by locale within dengue 
endemic countries, population density, social, economic, cultural, demographic and ecological factors such as temperature, season, rainfall and 
altitude. Accordingly, the risk of dengue infection varies widely between and within countries, and also from year to year, and season to season, as 
shown in a GeoSentinel analysis.7 In addition, the risk of dengue for travellers depends not just on these large-scale risk factors but upon specific 
activities in each dengue endemic destination.  
US travellers from the Boston Area Travel Medicine Network traveling to dengue endemic countries with a median length of travel of 21 days had 
a seroconverson rate by either anti-DENV IgM or IgG ELISA between 2.9 and 6.8%.69 In this study, the ratio of asymptomatic to symptomatic 
dengue was about 4 to 1. This asymptomatic to symptomatic ratio was also documented in another study: 85% travellers with lab-confirmed 
dengue infections had no history of dengue.70 For US travellers, the largest number of travel-acquired dengue infections occurred as a result of 
travel to the Caribbean, Mexico and Central America, followed by Asia.71 For travellers returning to Europe, South-East Asia was the most 
important destination for dengue acquisition, followed by Latin America, the Indian subcontinent, the Caribbean, and Africa.72 In GeoSentinel, 
which presents a more global picture, overall dengue cases varied monthly between Southeast Asia (June, September), South Central Asia 
(October), South America (March), and the Caribbean (August, October).7  
In most travellers` studies the attack rate of dengue cannot be determined due to the lack of a denominator. In Sweden, data both for legally 
notifiable dengue cases and travel volumes are available, making it possible to study attack rates. An increasing trend of symptomatic dengue 
infections for most tropical destinations among Swedish travellers.9 The attack rate was 13.6 (95% CI 12.7, 14.4) to Thailand, 45 for Sri Lanka and 
43 for per 100,000 travellers.  Table 1 summarizes the attack rates from different studies in travellers.  
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Sub-populations of travellers:  
Business travellers: Given that dengue is predominantly a disease of urbanized areas73, even short-term travel for business in cities poses risk. 
Expatriates in Delhi, India, were shown to be at higher risk for dengue than the endemic population.74  
Long-term travellers and persons with prolonged residence in dengue endemic countries (expats): The prevalence of positive dengue ELISA in 
travellers from non-endemic countries to dengue-endemic countries for more than 2 weeks but less than 1 year was 7%; for those who traveled for 
more than one year, it was 40%.70 The incidence of clinically apparent infections with laboratory-confirmation by a positive NS1 antigen test in 
Peace Corps Volunteers was 1.12 cases per 1000 volunteer-months, with the highest rate reported in the Caribbean region, with a rate of 5.51 cases 
per 1000 volunteer-months followed by the East Asia/South Asia region (3.34) and Central America (2.55).75 In pre-deployment and post-
deployment sera collected from US Army Special Operations Forces deployed to South and Central America, Africa, and Southeast Asia, the 
seroconversion rate was 13%.76 
Migrants: Despite increasing migration, including South-South migration77,78, little is known about the incidence of dengue in migrants.  In 
migrants now living in non-endemic countries returning to dengue endemic countries to visit friends and relatives (VFR), a higher risk of severe 
dengue compared to tourist travellers was documented in a GeoSentinel study79, which was most likely due to the fact that many of the VFRs 
already had a primary dengue infection and were hence at a higher risk of more severe dengue during their second infection. Dengue was shown to 
have increased in Colombia as a result of migration from Venezuela80, but no data exist on the incidence of dengue in migrants.  
Paediatric travellers: Although  dengue is primarily seen in children and adolescents in dengue endemic countries, dengue in paediatric travellers is 
rarely reported, most likely because the majority of travellers are adults. A primary infection in children is more likely to be mild or asymptomatic; 
however, secondary infections in children in endemic countries dispose more often to dengue shock, whilst in adults, internal bleeding is more 
frequent.81 The death rate for children aged 3-14 years was 14.5-fold higher than in young adults aged 15-39 years. The death rate rose somewhat 
in adults aged 50 years and older; hospitalizations due to dengue haemorrhagic fever showed the same trend as death rates.82 One unusual case in a 
8 year old traveller with severe dengue who presented with a nephrotic-range proteinuria.83 Children VFR may be at higher risk for severe dengue, 
similarly to adult VFR, due to second infection.84 
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Older travellers: Many travellers are older adults, and older travellers usually exhibit more co-morbidities. Diabetes has been identified as a risk 
factor during primary or secondary dengue infections for a more severe clinical course, and so have other co-morbidities such as hypertension, 
cardovascular disease and asthma.85,86  Dengue can result in diverse cardiac manifestations including myocardial dysfunction and a broad range of 
rhythm disturbances.87   
 
Travellers on anti-coagulants: Patients on anti-coagulants pose particular challenges; no guidelines exist when to stop and re-start anti-coagulant 
therapy during the critical phases of dengue with thrombocytopenia and bleeding tendencies. 
Pregnant travellers: Pregnant women are at higher risk for severe disease, especially during the third trimester.88,89 Two large epidemiological 
studies from Brazil indicate that symptomatic dengue during pregnancy is associated with an increased risk of preterm birth and fetal death though 
not with congenital malformations.90,91 Perinatal transmission to infants is recognised.92 Vertical transmission is common among mothers who are 
viraemic at delivery.93 But transplacental transmission is not thought to occur during infections that occur earlier during gestation, but formal data 
are lacking. Dengue virus was retrieved from 75% of 12 infected breastfeeding mothers, so transmission via breastfeeding is plausible although no 
cases have been reported.93  
Travellers with sickle cell disease: Persons with sickle cell disease are thought to be at increased risk of severe dengue, although the strength of 
the evidence is limited due to the scarcity of data in this population.94  
 
Severe dengue in travellers 
Travel medicine providers need to be aware of the complexities of risk assessments in travellers.95The absolute annual risk of severe dengue 
depends on many factors which include the transmission intensity in the destination country, the time interval to the preceding dengue infection, 
seasons and epidemic years, host and genetic factors, other flavivirus exposure, expertise in clinical management, and age. Severe dengue is 
overall a rare event, and therefore large prospective studies involving ten thousands of travellers are required in diverse geographic settings to 
determne the true risk of severe dengue in travellers. Such large studies do not exist for travellers. In the endemic population, many lessons can be 
gleaned from the Phase 3 trials by Sanofi Pasteur in 10 highly dengue endemic countries where 30,000 children were followed up for 6 years. The 
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placebo arm involved about 10,000 children aged 2 to 16, recruited in sites chosen for their high dengue transmission intensity. The risk for severe 
dengue was higher in younger children (ages 2-8 versus 9-16), and depended on serostatus: The absolute annual risk for severe dengue in dengue 
(Table 2). Such data cannot be extrapolated to travellers, as the duration of exposure is usually not a year, and there are differences in host, age, 
and background flavivirus exposure.  
Results from most published studies in travellers are based on passive surveillance, or referral centers, or sentinel surveillance, and hence the 
denominator is different, or even absent. Here we present some published data; none of them are prospective cohort studies: Of 219 imported 
dengue virus cases seen in 14 European centres, 17% had a secondary dengue infection.96 17 out of these 219 had any spontaneous hemorrhage, 
the majority of which were mild such as epistaxis or gum bleeding, and none required blood or platelet transfusions. In addition, only 2 patients 
met the WHO criteria for DHF, and none had dengue shock syndrome (DSS). Nevertheless, altogether 23 (11%) travellers had significant clinical 
manifestations (internal hemorrhage, plasma leakage, or marked thrombocytopenia) even if not fulfilling the criteria for DHF at the time. A 
secondary immune response was significantly associated with both spontaneous bleeding and other severe clinical manifestations.  In another 
study in US travellers, of 334 laboratory confirmed dengue infections, 12% were hospitalized and 2 died (1%).71  No deaths were described in a 
cohort of 242 acute dengue infections imported to Europe by returning travellers from 2012 to 2014.26  In 35 Israeli travellers hospitalized for 
laboratory confirmed dengue, 12 (34%) patients had sonographic signs of sub-clinical capillary leakage, which was found in 32% of primary 
dengue cases and in 40% of secondary dengue cases.97 However, as highlighted further below, sub-clinical fluid accumulation around the 
gallbladder, thickening of the gallbladder, or minor perihepatic fluid accumulation are not signs of nor reliably predictive of progression to severe 
dengue. Two patients with primary dengue infection presented as dengue haemorrhagic fever, underlining again that primary infections can also 
have severe manifestations.  
In a modelling study by Stanaway et al, the case fatality rate due to dengue was higher in the US compared to dengue endemic countries in Asia or 
Latin America.98,99 This could be a modelling artefact, or reflect the possibility that Western physicians are not familiar with the management of 
severe dengue. For example, a A female traveler was hospitalized with fever and abdominal pain after returning from Ecuador. Due to a suspected 
acute acalculous cholecystitis, cholecystectomy was performed. After cholecystectomy, severe spontaneous bleeding from the abdominal wound 
occurred and the patient died. Postmortem analysis of transudate and tissue demonstrated a DENV secondary infection and a gallbladder wall 
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thickening due to an extensive edema.100 This was an avoidable death if the physicians had recognized the diagnosis and understood the clinical 
course of dengue. Fortunately, overall, dengue deaths are rare. One death in a Norwegian traveller was due to a subarachnoidal haemorrhage 
related to thrombocytopenia, without otherwise criteria for dengue haemorrhagic fever.101 A traveller returning to the Netherlands presented with 
dengue-related encephalopathy. This patient had a primary dengue infection who, in the absence of overt signs of dengue shock syndrome, died 
due to progressive cerebral oedema. Autopsy findings demonstrated loss of integrity of cerebral vascular endothelium and involvement of 
complement activation.102 Among 82,825 ill Western travelers reported to GeoSentinel, one death was recorded due to severe dengue.103 In 
summary, dengue related deaths in travellers have been reported sporadically, were usually associated with secondary infections, but deaths have 
also occurred after primary infections.  
 
What is the risk of severe dengue following a secondary infection? 
This is a frequently asked question by travellers and travel medicine providers alike. Amongst the lay public and health professionals there is great 
concern and fear for travellers with a laboratory confirmed dengue infection from previous travel that a second infection would place such 
travellers at immense risk of severe dengue. It is an important question because it may have practical consequences including decisions to forego 
any repeat travel to dengue endemic countries and areas. Given that more than 128 countries are now dengue endemic, this would be a massive 
restriction on hundreds of thousands of travellers even not millions. There are also legal and litigation implications for employers or the military 
for deploying staff or military after a primary dengue infection to countries where such persons may be at risk of a secondary infection. 104As 
outlined above, given the absence of large prospective studies in travellers, we do not have an evidence base for providing appropriate risk 
assessments and counselling. Therefore we need to glean from epidemiological studies in endemic populations, and also on our pathophysiological 
understanding of severe dengue.  
Following a primary infection with one dengue virus serotype, protection against the infecting serotype (homotypic protection) is considered to be 
life long, while temporary cross-protection is induced to infection and/or disease accompanying infection with another serotype (heterotypic 
protection). The ADE phenomenon suggests that quantitative virus-infected cells determine disease severity. Accordingly, severe dengue can 
accompany first as well as secondary dengue infections. Both the risk and severity of secondary infections are higher than that of first dengue 
infections, as shown in various epidemiological studies.105-108 Recent modelling studies have provided better estimated for the incidence of 
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symptomatic dengue versus asymptomatic in primary versus secondary dengue infections: the proportion of infections that are symptomatic for 
first infections as 0.18 (95% Credible Interval, CI: 0.16, 0.20), 0.13 (95% CI: 0.05, 0.17) for individuals infected in the year following a first 
infection and 0.41 (95% CI: 0.36, 0.45) for those experiencing secondary infections after this first year.109 
The ratio of symptomatic versus inapparent outcomes in repeat dengue virus infections is influenced by the time interval between infections.110 
During the first year, cross-reactive antibodies appear to be protective against developing severe dengue, but with waning antibody titres over 
time, these cross-reactive antibodies then cause more severe dengue after about 2-3 years.111,112 In other words, travellers exposed to a second 
infection within the first 2 years may even be protected against severe dengue; disease enhancement is only observed after about 2-3 years, and 
this observation was also re-confirmed in the Sanofi Pasteur Phase 3 trials where the risk of severe dengue in seronegative vaccines was 
recognized after 30 months.113 Severe dengue is a multifactorial disease, it is hence important to re-emphasize that not only the time interval 
between the first and second infection, but also host factors, viral strain, age and experience in clinical management will determine any severe 
outcomes of the disease.55  
Not all secondary infections lead to severe dengue. Apparently a certain ratio of antibody to virus is needed which, while not quantifiable, was 
documented in two large prospective studies.53,114 Immune correlates for both protection and for disease enhancement are sorely missing.115 The 
most frequently reported proportion of secondary infections leading to severe dengue is 2-4%.35,116 
So what is the relative risk of severe dengue in a secondary infection versus primary infection? In a retrospective study in Bangkok, among all 
cases of severe dengue, 84% were due to secondary infections, and Relative risks (RR) of severe dengue accompanying a secondary infection 
versus primary infection was around 7.117 However, the sample size was small. In a larger cohort study in 4-9 year old children in Indonesia, the 
risk of severe dengue (DHF) was 4% for secondary infections, and no severe cases were noted in primary infections.118 Another prospective study 
reported a RR of 3.4.119 The recent completion of the long-term Phase 3 trials of CYD-TDV dengue vaccine provides 5 years of hospital based 
surveillance reporting on cumulative incidence of severe dengue in the placebo group of seronegative versus seropositive children aged 2 to 16. 113 
The  overall incidence over 5 years of severe dengue in seropositive individuals aged 2-16 was 6%, whereas the cumulative incidence was 2.5% in 
seronegatives, mounting to a RR of 2.42. The RR of severe dengue was higher in those aged 2-8 versus those aged 9-16  (Table 2).  
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Following recovery from a second infection a broadened immune response appears to be induced that prevents severe disease accompanying a 
third or fourth infection with different serotypes, as observed from natural cohort studies120, possibly explained by multitypic immunity.52 
 
Implications for Travel Medicine Practice 
 
Pre-Travel:  
(1) Pre-travel Counseling 
Every health care worker who counsels a prospective traveller to a dengue-endemic country has important educational responsibilities. He or she 
should prepare their patients to have a healthy trip. This includes guidance on how to avoid dengue infections but also clinical information to help 
the traveller be alert to the early or severe signs and symptoms of dengue should they occur during or shortly after their trip.  It is a responsibility 
of travel medicine personnel or any physician who sees a febrile patient recently returned from a dengue endemic country (virtually any tropical 
destination) is to assure that the patient is promptly seen by competent infectious disease specialists and provided with a specific warning to 
recognize early signs of vascular leakage.  
Counseling should include a fact-based description of the risk of being bitten by an infected Aedes aegypti or Aedes albopictus and accompanied 
by actionable advice on avoiding such bites. Excellent, authoritative and accessible information is available at the United States CDC “Dengue” 
website (https://www.cdc.gov/dengue/index.html). Aedes species are daytime biting mosquitoes that feed most actively in the early morning or late 
afternoon. Daytime visits to places where humans congregate including hotel grounds carries some risk of exposure to Aedes mosquitoes.  A 
greater risk occurs during daytime visits to homes or short or long-term residence with local residents. It seems likely that airbnb or counterpart 
home-residence programs will contribute to an increase in travel-acquired dengue.  The single most useful way to prevent Aedes bites is to stay 
inside air-conditioned structures. That may be impossible for the recreational tourist. Persons venturing into close contact with people in the 
country they are visiting should apply mosquito repellant to exposed skin prior to daytime exposure, particularly to the back of the neck, arms and 
legs. Unfortunately, compliance with repellent use on skin and clothing has been shown to be suboptimal in travellers.121 Potential difference of 
the efficacy between DEET and picaridin containing insect repellents applied at the same dosage are minimal, with some evidence pointing to a 
superior persistence for picaridin. Where only 30% DEET or lower concentrations are available, then on current evidence, it is reasonable to offer 
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DEET or picaridin as a first choice. Where >50% DEET products are available then the protection time advantage associated with these 
formulations make them the first choice repellents.122 
Pre-travel briefings should be accompanied by a description of a worst-case illness scenario. Adults with no recognized prior dengue infection are 
at risk to the dengue fever syndrome, a constellation of high fever, retro-orbital headache, gastrointestinal disturbances, aches and pains often 
described as “the worst illness I ever had.”  Young children without prior travel to dengue endemic countries may experience a mild febrile 
episode while the older child may experience variations of the dengue fever syndrome. If the travellers are residents in or VFR to dengue-endemic 
countries or have received the diagnosis of a prior dengue illness, counseling should include a description of dengue warning signs with strong 
emphasis that the traveller who develops a high fever should urgently seek competent medical care in a facility prepared to provide life-saving 
resuscitative care. 
All travellers need to be aware that the risk of more severe dengue is higher after a second infection with a different serotype, but that severe 
disease can also occur after a primary infection. Seeking care in settings experienced in the clinical management of severe dengue is highly 
advised. All fevers longer than 3 days should always be further investigated. The critical phase usually starts on day 4 or 5 of illness (Figure 1). 
With timely care and good clinical management, case fatality rates should be below 0.1%.  
(2) Vaccines to prevent dengue infections in travellers 
The high incidence of dengue in travellers to dengue endemic countries would justify pre-travel vaccination.123 The first licensed dengue vaccine, 
CYD-TDV (Dengvaxia®), is a live attenuated, recombinant tetravalent vaccine employing the attenuated YF virus 17D strain as the replication 
backbone. However, its performance is serostatus dependent being protective and safe in seropositive individuals, but not recommended for 
dengue-naive travellers due to an excess risk of severe dengue.124 Offering the vaccine to seropositive travellers is therefore possible, however, 
there are four drawbacks: First, the proportion of seropositives amongst travellers is low. For example, 5.8% of Italian travellers had dengue IgM 
and/or IgG antibodies.125 In Australian travellers, 4.4% were dengue IgG positive, and the number of prior trips to Asia was a predictor for higher 
dengue seropositivity.126  Second,  there are no diagnostic assays that can reliably determine serostatus.127 Third, the vaccine is licensed for 3 
doses, 6 months apart, which makes this vaccines practically unfeasible for last minute travellers. In 2018, CYD-TDV was approved by the 
European Medicine Agency for use in seropositive individuals, but use in travellers was not endorsed. In May 2019, CYD-TDV was also approved 
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by the U.S. Food and Drug Administration (FDA) but the recommendations by American Committee on Immunization Practices (ACIP) whether 
it will be recommended for travellers is still outstanding. The risk-benefit assessment of a serostatus-dependent vaccine such as CYD-TDV differs 
between travellers and the endemic population. Two other live-attenuated chimeric dengue vaccines are currently in Phase 3 trials, the results of 
which should be available by end 2019 or early 2020. One is a mixture of attenuated dengue 2 and chimeric dengue 1, 3 and 4 with backbone 
containing only the dengue 2 NS1 antigen, the other contains attenuated NS1-containing dengue 1, 3 and 4 viruses and a dengue 2/4 chimera.128 
These vaccines should result in a very different serostatus dependent performance from that of CYD-TDV.  Results of the Phase 3 trials are now 
eagerly awaited. 
 
Care for the Traveller with dengue during travel or after return from travel 
 
Diagnosis  
The choice of laboratory test depends on the time since onset of fever. Before day 5 of illness, during the febrile period, dengue infections may be 
diagnosed by virus isolation, by nucleic acid amplification tests such as reverse transcriptase-polymerase chain reaction (RT-PCR), or by detection 
of viral antigens such as the dengue non-structural protein 1 (NS1) by enzyme-linked immunosorbent assay (ELISA) or rapid diagnostic tests 
(RDTs). After day 4–5, dengue viruses and antigens disappear from the blood coincident with the appearance of dengue-specific antibodies, hence 
serological assays should be used.129  NS1 is longer positive than PCR, and hence the window for diagnosis is longer for NS1 based tests, 
especially in primary dengue.130 
Antibody response to dengue infection differs according to the immune status of the host. Patients not previously infected with a flavivirus 
develop a primary response characterized by a slow increase of specific antibodies. Dengue IgM antibodies are detected in about 50% of patients 
after days 3–5, increasing to 80% by day 5 and 99% by day 10.12 It is wise to wait until at least 5 days after onset of fever to interpret results of a n 
IgM/IgG ELISA or rapid diagnostic test.  IgM levels peak after 2 weeks and then decline to undetectable levels over 2–3 months. After primary 
dengue infections, anti-dengue IgG may be detected at low levels by the end of the first week (often only from day 10 onwards); the level 
increases slowly thereafter, and is thought to persist for life. In patients with a previous dengue (or other flavivirus) infection, dengue IgG titres 
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rise rapidly within the first week of illness. Serology does not determine the infecting virus serotype, is susceptible to cross-reactivity with other 
flaviviruses, and often requires paired acute and convalescent samples for confirmatory testing.  
The combination of NS1 antigen and IgM testing at point of care offers a longer diagnostic window and has revolutionized the diagnosis of 
dengue. Cross-reactivity with Zika virus and other flaviviruses is reported for all serological assays. Serostatus, reflecting whether or not the 
individual has experienced a dengue infection in the past, is determined by a serological assay. The specificity of a serological assay will depend 
on the extent of exposure to other flaviviruses, or vaccination with flavivirus vaccines such as TBE, YF or JE vaccines. No RDT has yet been 
validated or licensed specifically for the purpose of determining dengue-specific serostatus.131 Currently available RDTs that contain dengue IgG 




A wide variety of conditions, primarily viral infections but also bacterial and parasitic diseases must be considered in the differential diagnosis 
depending on local disease epidemiology, travel history, incubation time and the clinical picture. A very similar clinical disease to dengue occurs 
in many of the same travel destinations caused by chikungunya and Zika viruses, all transmitted by identical vector mosquitoes. Given the wide 
range of differential diagnosis, it is of utmost importance to exclude treatable diseases such as malaria and typhoid fever that can initially present 
similarly with fever and thrombocytopenia in order to institute prompt life-saving specific treatment. 
Clinical manifestations of severe dengue and management 
Clinical management of uncomplicated classical dengue fever has been reviewed extensively elsewhere and basically consists of symptomatic 
care, usually done on an outpatient basis, as long as daily monitoring of platelets and hematocrit is possible, and the patient is instructed to 
recognize warning symptoms and signs.81 Admission criteria vary by countries. Singapore, a low dengue endemic country, has proposed the 
following admission criteria: 
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• Objective criteria include significant bleeding, fall in blood pressure, dehydration and/or postural hypotension, a rise in the hematocrit ≥ 
20% above baseline, and a platelet count of less than 50,000/mm3 in adults or less than 80,000/mm3 in children. 
• Subjective criteria include severe vomiting or diarrhea, severe abdominal pain, persistent fever, dizziness, and age ≥ 65 years. 
With these criteria, the number of unnecessary hospitalisation was drastically reduced, without a concomitant increase in adverse clinical 
outcomes.132 
In the following, we focus on the management of severe dengue to reduce mortality. Every travel medicine provider and physician caring for ill 
returned travellers should be familiar with the clinical management of increased vascular permeability leading to intravascular volume depletion is 
the hall mark of severe dengue, which may progress to life-threatening dengue shock syndrome. Three Phases can be observed: the febrile phase 
with rapid decrease of platelets and increase of haematocrit, the critical phase, the recovery phase (Figure 1). Warning signs often occur at the time 
of defervescence and usually include irritability, abdominal pain, vomiting. Clinical detection of vascular permeability is based on a range of 
symptoms, signs and laboratory parameters, and as the progression to severe dengue can occur rapidly, such clinical assessments need to be done 
frequently, especially on days 4-6 of illness. Haemoconcentration of 20% or more is evidence of plasma leakage,133 but for individual case 
management this criterion is hard to apply since the baseline haematocrit is often not known, and hydration may mask this increase. Similarly, 
serosal effusions (pleural, peritoneal, and sometimes pericardial) reflect the severity of the vasculopathy but are difficult to detect clinically, and 
hence serial ultrasound investigations should be used to identify such vascular leakage.134 Ultrasound examination can detect plasma leakage in 
multiple body compartments, with ultrasonographic signs of plasma leakage preceding changes in hematocrits, sometimes even detectable in the 
first few days of illness. 46 Thickening of the gallbladder wall can frequently be detected, and is not necessarily a sign of severe dengue, as it can 
be detected in mild cases or primary infections.46, nor is sub-clinical perihepatic and perisplenic ascites.135 Pleural effusion and clinically apparent 
ascites are associated with progression to dengue hemorrhaegic fever. 134  Reflecting volume depletion, a highly characteristic phenomenon may be 
observed which should be taken very seriously: narrowing of the pulse pressure.  The pulse pressure is the difference between systolic and 
diastolic pressure. In early severe dengue, the diastolic pressure rises while the systolic pressure is maintained, resulting in narrowing of the pulse 
pressure. When the PP narrows to 20 mmHg or less, the patient is defined as having impending dengue shock. Although the patient may appear 
alert and well,  the significance of the narrow pulse pressure must not be ignored since without prompt fluid resuscitation the patient may 
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deteriorate rapidly. Clinical evidence of organ impairment is observed less frequently, except as a secondary phenomenon or in individuals with 
underlying diseases.85 Asymptomatic hepatomegaly and mild to moderate elevations of liver transaminases are extremely common (both in 
primary and secondary dengue), but fuliminant hepatitis is usually associated with secondary infection.136 
 In the absence of effective antiviral or immunosuppressive therapy, good supportive care is the cornerstone to reduce fatal outcomes. 
Prompt recognition and immediate fluid resuscitation is crucial. Titrating sufficient fluid replacement to maintain adequate intravascular volume 
for 48-72 hours until the vasculopathy reverses is the art of good clinical management of severe dengue.81 Fluid overload is a mistake of 
inexperienced clinicians that may result in pulmonary oedema and death. Figure 2 displays the consequences of too little or too much fluid. Causes 
of death are often related to either of the three delays: delay in admitting a patient with warning signs, delay in initiating fluid therapy during the 
critical phase, or delay in discontinuing fluid resuscitation in the recovery phase. Algorithms for the clinical management of compensated and 
decompensated shock both for adults and children are available from WHO`s 2009 Guideline on Diagnosis, Treatment, Prevention and Control 
Clinical.137 The use of prophylactic platelet transfusions for moderate to severe thrombocytopenia without clinical bleeding is controversial. In a 
recent trial in Asian adults with platelet counts below 20,000, prophylactic platelet transfusion was not superior to supportive care in preventing 
bleeding, but was associated with more adverse events.138   Significant predictors for mortality include gastrointestinal bleeding <72 h after 
presentation, and haemoconcentration and leukocytosis after hospitalization.139 Fluid resuscitation in pregnant women, small children, and those 
with co-morbidities need adapted fluid resuscitation and more frequent monitoring.  
The increased vascular permeability and abnormal haemostasis are in most cases transient and resolve within 48-72 hours under good clinical 
management, but individuals with post-dengue illness often remain tired and lethargic for weeks. Recovery can be particularly prolonged in adults, 
who may experience profound fatigue, myalgia and depression for weeks to months after the acute illness has resolved, irrespective of dengue 
severity.140 
Severe disease outcomes other than dengue shock syndrome: Although vascular leakage is the hallmark of severe dengue, other unsuual severe 
complications can also occur. Unusual complications include myocarditis141, other cardiac problems87,141,142 and fulminant hepatitis.143 Dengue can 
manifest with a wide range of neurological features, which have been noted in 0.5-21% of patients with dengue admitted to hospital.144 Although 
the association of Zika with Guillain-Barre Syndrome is much stronger, dengue can also trigger Guillain-Barre Syndrome.145,146 Haemophagocytic 
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syndrome is a rare event, but should be suspected in dengue cases with prolonged fever. The clinical picture is characterized by persistent high 
fever, variable cytopenia and multi-organ failure associated with macrophage activation, haemophagocytosis and hypercytokinaemia.147  Table 4 
summarizes rare severe dengue related complications, described in the endemic and travellers`populations.  
Conclusions: 
As in the endemic population, dengue has a high morbidity but low mortality in travellers. Although dengue is a frequent cause of travel illness, 
severe dengue and deaths are rare. Nevertheless, dengue infections can interrupt travel, lead to evacuation and major out-of-pocket costs. Dengue 
is more frequent than many other travel-related vaccine preventable diseases such as hepatitis A, hepatitis B, rabies, Japanese encephalitis, and 
yellow fever, indicating a powerful need for a dengue vaccine for travellers. Results of efficacy trials of two new tetravalent dengue vaccines are 
imminent.  
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Table 2: Relative Risk (RR) of severe dengue in seronegative compared with seropositive children; data derived from the placebo group in the 
Phase 3 trials of the CYD-TDV dengue vaccine113 
 
Cumulative incidence (CI) of severe dengue per 1,000 unvaccinated 
children in the Phase 3 trial CYD-TDV 
Relative  
Risk (RR) 
2-8 years old RR 
  Seronegative Seropositive 




9-16 years old RR 




2-16 years old RR 














Table 3: Overview on pertinent data with regards to risk of severe dengue associated with secondary infections derived from studies in dengue 
endemic populations 
 
Key messages Source 
About 2-4% of secondary infections lead to severe dengue 35,116,118 
The proportion of infections that are symptomatic for first infections as 0.18, 0.13  for individuals infected in the year following 
a first infection and 0.4% for those experiencing secondary infections after this first year.  
109 
Among all cases of severe dengue, 84% are due to secondary infections 117 
Relative Risk of severe dengue as a result of secondary infection versus primary dengue infection is 7 (Thailand) 118 
Relative risk of severe dengue as a result of secondary infection versus primary infection is 3.4 (Indonesia) 119 










Table 4: Examples of rare complications of dengue infection in the endemic and travellers`population 
 Diagnoses Selected references 
Cardiovascular Myocarditis 141 
 Bradycardia 87,141,142 
Liver Fulminant hepatitis 143 
Neurology Encephalopathy 148 
 Encephalitis 148 
 Cerebral infarcts 148, 149 
 Guillain-Barre Syndrome 145,146,150-154 
 Abducence nerve palsy 155 
 Rhabdomyolysis 156 
Eye Retinal vasculopathy and optic 
neuropathy 
144 
 Optic neuritis 157 
Haematology Haemophagocytic syndrome 147 




















- capillary	refill<2	seconds																				 - Worsening	pleural	effusion
Hypotensive	shock																																							- Normal	heart	rate																																														 and	ascites.
- Normal	blood	pressure																									 - Clinical	deterioration
- Bleeding																																																								- Normal	pulse	pressure
- DIC																																																																		- Urine	0.5ml/kg/hr.
- Multi-organ	failure																																						- HCT	to	normal	
- Improving	acid-base
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